Loading…
← CockpitCompetitor Analysis › 290650.KS L&C BIO Co., Ltd.Open in the cockpit ↗

L&C BIO Co., Ltd.290650.KSCompetitor analysis, valuation and peers

South Korea · KRW·Health Care›Medical Specialties

Korean biomaterials company making human/animal tissue-derived implants for dental, orthopedic and skin-regeneration procedures.

Momentum weak 26
Mkt cap
$943M
US dollars, full cap
Free float
73%
of shares outstanding
$/day
$7.31M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-3.5 pp
WACC 8.7%
Hurdle
+12 pp
Req g minus delivered
Next earnings
124 days
22 Mar 2027
Close · KRW₩20,100
1D+3.7%
1W-10.9%
1M-36.5%
3M-24.0%
6M-36.9%
YTD-32.0%
1Y-20.7%
ATR %11.6%
52w lowhigh66.8% off high

What L&C BIO does

Korean biomaterials company making human/animal tissue-derived implants for dental, orthopedic and skin-regeneration procedures.

Sells processed tissue products from human donors, such as acellular dermal matrix, a graft used in reconstructive and aesthetic surgery, as well as bone and dental grafts, mainly through distributors in Korea and abroad. Each product needs separate regulatory approval, so launches follow approvals market by market.

Products and services

  • Dental bone-graft materials
  • Orthopedic tissue implants
  • Skin-regeneration biomaterials

Customers

  • Dental clinics/hospitals
  • Orthopedic surgeons

Where it sits in the supply chain

  • Medical devices/biomaterials
  • Tissue-derived implants (allografts)
  • Dental/orthopedic/skin-regen supply…

What could go right

  • Dental/orthopedic implant demand growth
  • Export market expansion

What could go wrong

  • Regulatory approval risk
  • Reimbursement/pricing pressure

Moat: narrow (regulatory licence, process know-how). Tissue-processing and regulatory approvals for implantable biomaterials are hard to replicate quickly.

Headquarters: Seoul, South Korea · Employees: 155

L&C BIO at a glance

Size L&C BIO (290650.KS) is a South Korea Health Care company (Medical Specialties) with a market value of $943M, the 245th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩20,100 on 18 Nov 2026.

Performance Over six months the shares fell 36.9%, against -12.1% for the median peer and -37.2% for the South Korea market (cap-weighted) — 2nd lowest of 21 in its peer set.

Growth Revenue grew 65.3% over the last twelve months (peer median +6.1%); the operating margin is 20.0% (peer median 8.9%).

Valuation It trades at 9.7× enterprise value to sales against a peer median of 3.1× (4th most expensive of 21).

Price implies For today's price to make sense, revenue must grow about 33% a year for seven years (Req g). Recent delivered growth is +21%, so the hurdle is +12 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 3.5 points below its cost of capital (8.7% WACC).

Next results Next results expected around 22 Mar 2027 (exchange calendar; dates can move).

Relative performance

10015021 May 202621 Aug 202618 Nov 2026Peer median 88290650.KS 65
Six months, rebased to 100: L&C BIO against the median of its 20 peers (local-currency closes).

L&C BIO financials

Reported figures in KRW; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₩132B₩85.5B₩72.0B₩65.9B₩52.6B
Revenue growth—+19%+9%+25%—
Gross profit₩74.8B₩41.3B₩33.4B₩31.8B₩25.6B
EBITDA₩38.9B₩11.6B₩10.1B₩12.7B₩13.7B
Net income-₩93.2B-₩138B₩142B₩48.4B₩4.54B
Free cash flow₩2.34B-₩3.25B-₩13.3B-₩36.6B-₩43.6B
Capital expenditure₩36.1B₩17.0B₩5.35B₩25.0B₩37.7B
Total debt₩62.4B₩92.2B₩124B₩82.1B₩81.9B

Quarterly statements and history in the cockpit →

L&C BIO competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%+40%-20%0%7780SFL30467730KURNAORT300143BVSCBLL3015803002066885753006856886266882776523301021600055EUZ290650.KS6-month return →1-month return →
Up and to the right = strong over both horizons. L&C BIO is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%+60%5×10×7780SFL30467730KURNAORT300143BVSCBLL6885753006856887676886266882776523301021600055EUZ290650.KSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. L&C BIO is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%SFL30467730300143BVS3015803002066885756523301021290650.KSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. L&C BIO is the large dot.

L&C BIO competitors and peer comparison

How L&C BIO compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

L&C BIO against its 20 peers (data as of 18 Nov 2026)
Measure290650.KSPeer medianRank in peer set
1-month return-36.5%-6.1%lowest of 21
6-month return-36.9%-12.1%2nd lowest of 21
Distance from 52-week high-66.8%-32.1%2nd lowest of 21
Revenue growth (TTM)+65.3%+6.1%highest of 21
Operating margin20.0%8.9%4th highest of 21
EV / Sales9.7×3.1×4th most expensive of 21
Growth the price implies (Req g, 7 yrs)32.6%5.9%2nd most demanding of 13
Growth delivered (Del g)+21.0%+11.9%2nd highest of 13
Hurdle (Req g minus delivered)+11.6 pp-4.5 pp2nd most demanding of 13
ROIC minus cost of capital-3.5 pp+2.8 pp7th lowest of 20
EV / EBITDA32.8×9.5×2nd most expensive of 10
Net debt / EBITDA0.3×0.3×5th least indebted of 10

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
L&C BIO 290650.KSSouth Korea$943M-37%+65%20%9.7×32.6%+21.0%
Menicon 7780.TJapan$944M+26%+6%9%1.5×n/an/a
Safilo SFL.MIItaly$953M+42%-4%9%0.9×1.3%+4.7%
JINS 3046.TJapan$963M-8%+14%10%1.3×-6.1%+11.7%
Mani 7730.TJapan$965M-7%+10%30%3.9×3.3%+13.9%
Kuros Biosciences KURN.SWSwitzerland$907M-12%+41%6%5.5×n/an/a
Artivion AORTUnited States$905M-18%+14%5%2.6×n/an/a
INKON Life Technology 300143.SZChina$985M-23%+22%12%3.1×10.7%+12.9%
Bioventus BVSUnited States$895M-3%+4%10%2.0×7.5%+12.1%
Ceribell CBLLUnited States$995M+42%+31%-70%8.3×n/an/a
Aidite (Qinhuangdao) Technology 301580.SZChina$888M-12%+17%18%4.0×19.3%+23.3%
Edan Instruments 300206.SZChina$1.00B-19%+14%17%2.5×6.9%-2.9%
Shenzhen YHLO Biotech 688575.SSChina$882M-16%+3%12%3.1×2.0%+12.7%
Amoy Diagnostics 300685.SZChina$1.01B-15%+7%34%4.7×4.9%+10.4%
Hangzhou Biotest Biotech 688767.SSChina$878M-12%-4%3%10.4×n/an/a
Xiangyu Medical 688626.SSChina$877M-38%0%4%7.2×n/an/a
Tinavi Medical Technologies 688277.SSChina$872M-36%-2%-59%21.7×n/an/a
PHC 6523.TJapan$1.02B+34%+3%8%0.9×-4.0%+3.5%
Inno Laser Technology 301021.SZChina$1.03B-33%+17%9%11.1×50.8%+8.6%
Beijing Wandong Medical Technology 600055.SSChina$1.03B-26%-11%-33%3.0×n/an/a
Eckert & Ziegler EUZ.DEGermany$1.03B-2%+4%26%2.7×7.7%+12.1%

Questions

Which companies are L&C BIO's closest peers?
The cockpit's peer set: Menicon (7780.T), Safilo (SFL.MI), JINS (3046.T), Mani (7730.T), Kuros Biosciences (KURN.SW), Artivion (AORT), INKON Life Technology (300143.SZ), Bioventus (BVS).
Is L&C BIO expensive compared with its peers?
On ev / sales it trades at 9.7× against a peer median of 3.1×, 4th most expensive of 21 in its peer set. For today's price to make sense, revenue must grow about 33% a year for seven years (Req g). Recent delivered growth is +21%, so the hurdle is +12 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has L&C BIO stock performed?
Over six months to 18 Nov 2026 the shares returned -36.9% against -12.1% for the median peer; over one year -20.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.